Allergy Shots Insurance: Five Structural Drivers of Your Bill

Your deductible is the single most variable cost driver for allergy shots. High-deductible health plan (HDHP) enrollees who start the build-up phase in Q1 — when deductibles reset every January 1 — owe the full commercial allowed amount on every visit until the deductible is burned down. A 40-allergen skin test at a freestanding clinic carries an allowed amount of approximately $410 (anchored to Sidecar Health benchmarks and CMS 2025 PFS 95004 at $3.56 per allergen x 40); that patient owes all $410 before the insurer pays a cent. Strategy: schedule initial skin testing and first build-up visits early in the plan year so the deductible is met before the bulk of the 26-week build-up phase. Post-deductible HDHP coinsurance at 20% converts a $307 allowed visit into approximately $61 — far more manageable. The IRS-qualified HDHP minimum deductible is $1,650 for self-only coverage in 2026.

Copay stacking is what happens when a nominally covered plan charges a per-visit specialist copay on every injection visit across the full 3–5-year SCIT course. Stachler RJ (AAOA, December 2, 2020) calculated: 'Most insurance companies will charge a co-pay per shot. These co-pays can be up to $20 a shot (every week for 52 weeks per year and for up to 3 years: $20 x 52 weeks x 3 years: $3,120 at the minimum).' This is why a commercially covered patient who pays $0 per vial preparation day can still accumulate $3,120 in copays before a single injection is covered at $0. For context, this minimum assumes only $20 per shot (commercial allowed amounts are $15.10–$18.05 per CPT 95117 per PayerPrice April 2026), once-weekly injections, and a 3-year course — all conservative assumptions. Patients on a twice-weekly build-up schedule or a 5-year maintenance course face proportionally higher stacking.

Prior authorization requirements vary significantly by carrier. Aetna Clinical Policy Bulletin CPB 0038 covers in-office SCIT without prior authorization for documented IgE-mediated allergic rhinitis, conjunctivitis, asthma, or hymenoptera sensitivity. Cigna Coverage Policy mm_0070 also typically waives PA for in-office SCIT, though it requires authorization for FDA-approved sublingual immunotherapy tablets (Grastek, Oralair, Ragwitek, Odactra) under the pharmacy benefit. Anthem regional BCBS plans generally require PA and reauthorization at the 3–5-year mark per Anthem BCBS Healthkeepers Virginia LAB.00027. BCBS PPO regional policies vary: most do not require PA for standard in-office SCIT. The most operationally consequential 2022–2025 policy change is not a PA rule but the UHC home-administered SCIT exclusion effective January 1, 2023, which ended coverage for any SCIT administered outside an office setting regardless of PA status. Step-therapy — requiring failed pharmacotherapy before approving biologics or SLIT tablets — applies to Xolair, Dupixent, and FDA tablets, not to in-office SCIT.

A copay is a flat dollar amount per visit regardless of the allowed amount — for example, a $20 specialist copay on a BCBS PPO visit (representative case anchored to PayerPrice BCBS national avg $16.69 for CPT 95117). Coinsurance is a percentage of the allowed amount — 20% coinsurance on Medicare Part B converts a $158.82 allowed maintenance visit (CPT 95117 + 95165 x 10) into $31.76 patient obligation after the $283 deductible (2026). For commercially insured SCIT patients, flat-copay designs are more predictable than coinsurance, since the vial-preparation line item (CPT 95165) pushes allowed amounts higher on prep days. A 10% coinsurance plan (Cigna, representative case anchored to PayerPrice Cigna $18.05 for 95117) produced a $30 patient bill on a $194.55 allowed visit. The CY 2026 PFS Final Rule (CMS-1832-F, FR Doc 2025-19787) raised the conversion factor 3.26% to $33.40, modestly increasing 2026 Medicare allowed amounts.

For SCIT, in-network means your allergist has a contracted allowed amount with your insurer — the amount the insurer has agreed to pay. Out-of-network means the insurer either pays nothing (closed HMO) or applies a higher coinsurance rate, often 40–50%, on an uncontracted amount. Most commercial plans require in-network care for SCIT. The UHC home-administration exclusion since January 1, 2023 adds another in-network layer: even a contracted in-network provider cannot bill for home-administered SCIT under UHC commercial plans — care must be in-office. Before starting shots, confirm with your insurer: (1) that the allergist and facility are in-network; and (2) whether the facility has been reclassified as a hospital outpatient department, since HOPD billing generates a facility fee on top of the in-network professional fee regardless of in-network status.

California Medi-Cal covers the injection code (CPT 95117) at approximately $11.66 — below Medicare's $11.97 national allowed amount. However, per the DHCS Medi-Cal Allergy Manual Part 2 (Allergy Testing and Desensitization), CPT codes 95120 through 95134 and 95145 through 95165 are explicitly listed as non-benefits. This means antigen-preparation codes — the codes practices use to bill for the allergen extract vials — are excluded from Medi-Cal reimbursement. Practices facing this coverage gap either absorb the antigen cost themselves, require patients to source antigen from elsewhere, or decline to see Medi-Cal SCIT patients entirely. Patient cost share for the injection visit is $0, but the practice's ability to sustain Medi-Cal SCIT service depends on internal economics. This is the largest Medicaid antigen-prep coverage gap in the US and is frequently missed by patients and providers operating outside California.

HOPD stands for Hospital Outpatient Department. When a hospital acquires a freestanding allergy practice and reclassifies it under Medicare's Outpatient Prospective Payment System (OPPS), it gains the right to bill a facility fee on top of the professional fee for every visit. A 40-allergen skin test panel with a $142.40 Medicare-allowed professional fee became a $24,400 billed encounter at M Health Fairview HOPD (Kaitlin Johnson case, PBS NewsHour 2024). At Geisinger Scenery Park — acquired by Risant Health, a Kaiser Permanente non-profit subsidiary — the same type of procedure generated a $1,711 patient bill in 2026 (WPSU Public Radio, March 24, 2026). Identify HOPD status by calling the billing department and asking: 'Is this location a provider-based hospital outpatient department?' Colorado HB23-1215 and Connecticut HB 6669 restrict some HOPD facility fees; Pennsylvania has no equivalent law as of May 2026.